IMW 2019 oral presentation

September 15, 2019

Oncopeptides presented new interim data in RRMM Patients with Extramedullary Disease (EMD) from the Pivotal Phase 2 Horizon-study at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The data focused on patients with extramedullary disease (EMD) and was presented in an oral presentation by Professor Paul G. Richardson.

See the interview with Professor Paul G. Richardson by OncLive TV. Below is also the oral presentation as PDF and a link to an article in OncLive.

Read Article in OncLive:

Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease – Article in OncLive